Roxanol Articles
King swings to loss in 1st qtr on Alpharma costs
12 May 2009
UPDATE: Ligand's 1st-qtr 2009 loss deepens 30%
12 May 2009
Stock Commentary - New York week to April 20, 2009
23 April 2009
FDA OKs unapproved opioid due to shortage
16 April 2009
FDA blocks unapproved narcotics marketing
1 April 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
King's Embeda "effective for up to 12 months"
9 February 2009
King divests drug to clear Alpharma merger
12 January 2009
Alpharma relents, accepting King Pharma
1 December 2008
Stock Commentary - New York week to Nov 17, 2008
24 November 2008
UPDATE: King "committed" to $1.4B bid for Alpharma, seeks to strengthen painkiller franchise
1 September 2008
King's profit drops 34% in 2nd-qtr 2008 to $43M
18 August 2008
Stock Commentary - New York week to April 7, 2008
14 April 2008
Stock Commentary - New York week to Feb 25, 2008
3 March 2008
Stock Commentary - New York week to Feb 11, 2008
18 February 2008
Stock Commentary - New York week to Feb 4, 2008
11 February 2008
Actavis challenges King's Avinza patent with ANDA filing
24 September 2007
King's 2nd-qtr revenue rises 9%, net income falls
20 August 2007
Stock Commentary - New York week to June 18, 2007
25 June 2007
King's 1st-qtr 2007 revenue increases 7%
21 May 2007
Ligand completes sale of Avinza to King
5 March 2007
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
FDA Approval for Alpharma's Kadian 80mg
6 November 2006
Ligand sells oncology line to Eisai and Avinza to King for total $518M
18 September 2006
Abraxis completes purchase of AstraZeneca brands
3 July 2006
Ligand's 1st-qtr 2006 revenues up 38%
29 May 2006
Shionogi's 2005 sales 196.4B yen, down 1.5%
29 May 2006
Ligand's Avinza fares well against oxycodone
15 May 2006
Ligand's full-year 2005 loss improves 19%
27 March 2006
Stock Commentary - New York week to Jan 23
30 January 2006
Shionogi's fiscal half-year revenue up 1.6%
12 December 2005
Good 1st-qtr results for Shionogi
22 August 2005
Alpharma's 2nd qtr sees 16% revenue rise
15 August 2005
FDA requests label change for Ligand's Avinza
8 August 2005
Alpharma to change Kadian labeling
1 August 2005
Stock Commentary - New York
28 March 2005
Japan stock market week to March 7
14 March 2005
Shionogi's 3rd-qtr sees sales drop 2.9%
21 February 2005
Ligand sets up pain and oncology units
15 November 2004
Ligand faces false information suit
30 August 2004
Shionogi profits up on plan, sales decline
23 August 2004
Ligand fails to meet 2nd-qtr expectations
16 August 2004
MGI and Alpharma in Kadian promotion deal
19 July 2004
Ligand's product sales rocket 80% for 1st-qtr
10 May 2004
Stock Commentary - New York
15 March 2004
Shionogi sales in line with forecasts
16 February 2004
Elan completes $102M product disposal
8 December 2003
Stock Commentary - New York
3 November 2003
Elan to sell pain products to aaiPharma
27 October 2003
Ligand raises $47M in private placing
22 September 2003
R&D costs offset 140% sales rise at Ligand
18 August 2003
Paladin's earnings up for full-year 2002
17 February 2003
SkyePharma licenses key drugs to Endo
13 January 2003
Ligand launches Avinza in USA
15 July 2002
Stock Commentary - New York
1 April 2002
Ligand gets US OK for Avinza morphine brand
25 March 2002
Ligand revenues leap 59%, as product sales double
18 March 2002
Ethypharm launch
26 November 2001
Positive Ph II for CeNeS morphine variant
30 January 2001
SkyePharma looking to move into the black
3 September 1999
FDA Says Depotech's DepoCyt "Non-Approvable"
27 May 1998
Sanofi Winthrop Launch Morcap In UK
30 September 1996
Mallinckrodt Group's Analgesics US FDA Approved
2 September 1996
Zeneca Licenses Faulding's Oral Morphine
4 March 1996
Smaller US Drug Firms Performed Well In 2nd Qtr
14 August 1995
First Launch Of Glaxo, Faulding's Kapanol
8 August 1994
Showing 1-73 of 73 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
